1. Alternative-Donor Hematopoietic Stem Cell Transplantation with Post-Transplantation Cyclophosphamide for Nonmalignant Disorders 
Orly R. Klein, Allen R. Chen, Christopher Gamper, David Loeb, Elias Zambidis, Nicolas Llosa, Jeffrey Huo, Amy E. Dezern, Diana Steppan, Nancy Robey, Mary Jo Holuba, Kenneth R. Cooke, Heather J. Symons 
Biology of Blood and Marrow Transplantation 
Volume 22, Issue 5, Pages (May 2016)
DOI: /j.bbmt
Copyright © 2016 American Society for Blood and Marrow Transplantation Terms and Conditions

2. Figure 1
Preparatory regimens, including (A) alemtuzumab, fludarabine, melphalan, TBI; (B) alemtuzumab, fludarabine, and melphalan; and (C) alemtuzumab, fludarabine, and TBI. G-CSF indicates granulocyte colony-stimulating factor; BMT, bone marrow transplantation.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2016 American Society for Blood and Marrow Transplantation Terms and Conditions

3. Figure 2
Median laboratory values at specified time points. Dotted line represents upper limit of normal. (A) Creatinine (mg/dL), (B) bilirubin, total (mg/dL), (C) aspartate transaminase (AST) (U/L), and (D) alanine transaminase (ALT) (U/L).
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2016 American Society for Blood and Marrow Transplantation Terms and Conditions